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Human African trypanosomiasis (HAT), a neglected tropical disease, is fatal without treatment. Pentamidine, a cationic di-
amidine, has been used to treat first-stage (hemolymphatic) HAT since the 1940s, but it is ineffective against second-stage (me-
ningoencephalitic, or central nervous system [CNS]) infection. Novel diamidines (DB75, DB820, and DB829) have shown prom-
ising efficacy in both mouse and monkey models of first-stage HAT. However, only DB829 cured animals with second-stage
infection. In this study, we aimed to determine the mechanisms underlying the differential efficacies of these diamidines against
HAT by conducting a comprehensive pharmacokinetic characterization. This included the determination of metabolic stability
in liver microsomes, permeability across MDCK and MDR1-MDCK cell monolayers, interaction with the efflux transporter
MDR1 (P-glycoprotein 1 or P-gp), drug binding in plasma and brain, and plasma and brain concentration-time profiles after a
single dose in mice. The results showed that DB829, an azadiamidine, had the highest systemic exposure and brain-to-plasma
ratio, whereas pentamidine and DB75 had the lowest. None of these diamidines was a P-gp substrate, and the binding of each to
plasma proteins and brain differed greatly. The brain-to-plasma ratio best predicted the relative efficacies of these diamidines in
mice with second-stage infection. In conclusion, pharmacokinetics and CNS penetration influenced the in vivo efficacies of cat-
ionic diamidines against first- and second-stage HAT and should be considered when developing CNS-active antitrypanosomal
diamidines.
Human African trypanosomiasis (HAT; sleeping sickness) is aneglected tropical disease caused by subspecies of Trypano-
soma brucei and is endemic to sub-Saharan Africa (1). HAT ap-
pears in two stages, the hemolymphatic stage (first stage), when
parasites are confined to the blood and lymph, and the meningo-
encephalitic stage (second stage), when parasites infect the central
nervous system (CNS), which accounts for the majority of diag-
nosed cases (2, 3). Without treatment, HAT leads to coma and,
eventually, death. Current treatments for second-stage HAT in-
clude melarsoprol, eflornithine monotherapy, and nifurtimox-ef-
lornithine combination therapy (NECT). However, these treat-
ments are limited by inconvenient parenteral injections, complex
infusion schedules, increasing treatment failure, and/or severe
toxicity (1, 3). Hence, new or improved chemotherapeutic agents
are needed for second-stage HAT.
Pentamidine, an aromatic diamidine (Fig. 1), has been used to
treat first-stage HAT since the 1940s, typically via intramuscular
injection (4). However, it is ineffective against second-stage HAT
due to low blood-brain barrier (BBB) permeability (5). DB75
(furamidine) is a structural analogue of pentamidine (Fig. 1) and
possesses potent in vitro antitrypanosomal activities (50% inhib-
itory concentrations [IC50s] of 10 ng/ml against wild-type T.
brucei strains) that are similar to those of pentamidine (6). Pent-
amidine and DB75 partially cured mice with acute (first-stage)
infection of the Trypanosoma brucei rhodesiense STIB900 strain
(2/4 and 3/4, respectively, at 4 doses of 20 mg/kg of body weight/
day administered intraperitoneally [i.p.]) (6). However, neither of
the two drugs was curative in the GVR35 CNS (second-stage)
mouse model (unpublished data for pentamidine) (6).
In search of safe and CNS-active antitrypanosomal diamidines,
we synthesized azadiamidines (e.g., DB820 and DB829) (Fig. 1) in
which one (or both) benzene ring was replaced by a pyridine ring.
DB820 and DB829 had potent in vitro antitrypanosomal activities
(IC50s of 40 ng/ml [or 90 nM] against wild-type T. brucei
strains), albeit they were less active than pentamidine and DB75 by
2- to 8-fold) (6). However, DB820 and DB829 (at 4 doses of 10
mg/kg/day i.p.) were 100% curative in the STIB900 acute mouse
model (6), which was markedly more active than pentamidine and
DB75. Moreover, DB829 (at 10 doses of 20 mg/kg/day i.p.) unex-
pectedly cured all animals in the GVR35 CNS mouse model,
where cure was defined as survival for more than 150 days post-
treatment without parasitemia relapse (6). Prompted by this ob-
servation, DB829 was tested further in the vervet monkey model
of second-stage HAT via intramuscular injection, and it cured all
infected monkeys (7). As such, DB829 was the first cationic di-
amidine that cured animals with CNS infections and has been
considered a front-running preclinical candidate for the treat-
ment of second-stage HAT (1, 8).
To elucidate the mechanisms underlying the differential effi-
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cacies of these cationic diamidines, a comprehensive pharmaco-
kinetic (PK) study was warranted to compare metabolic stability,
plasma/tissue binding, BBB permeability, and systemic and brain
exposures for pentamidine, DB75, DB820, and DB829. Further-
more, correlations of these measurements with in vivo efficacies
were made to reveal the properties that best predicted in vivo effi-
cacy against first- and second-stage HAT. These results will con-
tribute to the understanding of the in vivo drug action of antit-
rypanosomal diamidines and should be considered when further
developing CNS-active diamidines to treat HAT.
MATERIALS AND METHODS
Chemicals. Hydrochloride salts of DB75, DB820, DB829, and deuterated
DB75 (DB75-d8; with deuterated phenyl rings) as an internal standard
were synthesized as previously reported (9, 10). Pentamidine isethionate
was purchased from Sigma-Aldrich (St. Louis, MO). Mouse liver micro-
somes (MLM; from a pool of 833 male mice) were purchased from Xeno-
Tech LLC (Lenexa, KS). Liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS)-grade water, methanol, formic acid, Hanks’ balanced
salt solution (HBSS) with calcium and magnesium, and HEPES buffer
were purchased from Fisher Scientific (Pittsburgh, PA). Lucifer yellow
(LY), digoxin, digitoxin, midazolam, D-glucose, dimethyl sulfoxide
(DMSO), trifluoroacetic acid, trypsin-EDTA, and NADPH tetrasodium
salt were purchased from Sigma-Aldrich. Dulbecco’s modified Eagle me-
dium (DMEM) with no glutamine or sodium pyruvate, fetal bovine se-
rum (FBS), penicillin-streptomycin mixtures, L-glutamine, sodium pyru-
vate, and MEM (minimum essential medium) nonessential amino acids
(NEAA) were purchased from Life Technologies (Grand Island, NY).
Animals. Animal study protocols were approved by the Institutional
Animal Care and Use Committees (IACUCs) of the University of Kansas
and the University of North Carolina at Chapel Hill. Male Swiss Webster
mice (20 to 25 g) were purchased from Charles River Laboratories
(O’Fallon, MO). Clean room-housed mice were kept under filtered,
pathogen-free air in a 12-h light/dark cycle. Food pellets and water were
available ad libitum.
Cell culture. Madin-Darby canine kidney (MDCK) cells were main-
tained in DMEM containing 10% (vol/vol) FBS, 1% (vol/vol) NEAA, 1
mM sodium pyruvate, 4 mM L-glutamine, and penicillin-streptomycin
(100 units of penicillin and 100 g of streptomycin per ml) and cultured
at 37°C under 5% CO2 and 95% relative humidity. Cells were passaged at
80 to 90% confluence using trypsin-EDTA solution.
pKa, logD7.4, and metabolic stability determinations. The pKa and
logD7.4 (logarithm of distribution constant at pH 7.4) values of each di-
amidine were experimentally measured by pION Inc. (Woburn, MA) us-
ing a spectrophotometric method with methanol as a cosolvent (11). Met-
abolic stability was evaluated using MLM supplemented with NADPH.
Microsomal incubations were carried out as described previously (12),
with modifications. Briefly, diamidines were dissolved in water and added
to the incubation buffer to achieve final concentrations of 1.0 and 10 M,
which represented plasma concentrations observed in the mouse pharma-
cokinetic study described below. The microsomal protein concentration
was 0.5 mg/ml during incubation. Reactions (in triplicate) were allowed
to proceed for up to 60 min at 37°C and were quenched with 20 volumes
(vol/vol) of 7:1 (vol/vol) methanol/water containing 0.1% (vol/vol) trif-
luoroacetic acid and 10 nM internal standard (DB75-d8). After centrifu-
gation, the supernatants were analyzed by ultra-performance LC (UPLC)-
MS/MS to quantify the amount of substrate remaining. Pafuramidine
(DB289) served as a positive control for microsomal catalytic activity (13).
Microsomal half-life (t1/2) values were obtained by fitting percentage of
substrate remaining-time curves to the one-phase exponential decay
equation (C  C0  e
k · t; t1/2  0.693/k), where C0, k, and t are initial
concentration, rate constant, and time, respectively.
BBB permeability and P-gp-mediated efflux assays. To compare the
permeability of diamidines across the BBB, the MDR1-transfected MDCK
(MDR1-MDCK) cell monolayer model was chosen as an in vitro BBB
model due to its simplicity and its similar predictability when compared
to other existing in vitro models that use cells derived from brain endo-
thelium (14–16). The bidirectional permeabilities, apical-to-basolateral
(A-B) and basolateral-to-apical (B-A), of diamidines across the wild-type
(WT) MDCK and MDR1-MDCK cell monolayers were determined as
described previously (17). Briefly, transwell inserts (12-mm diameter and
0.4-m pore size; Corning, Inc., Tewksbury, MA) were preincubated with
culture medium for 1 h at 37°C and then seeded with 2  105 cells/ml (0.5
ml per insert well). MDCK cell monolayers were cultured for 5 to 7 days
before use. Permeability assays (in triplicate) were initiated by replacing
medium in the donor chamber with transport medium containing a test
compound. The transport medium consisted of HBSS containing 10 mM
HEPES and 25 mM D-glucose at pH 7.4. The compound concentrations in
the donor chamber were 1 and 10 M for diamidines (representative of
plasma concentrations observed in the mouse pharmacokinetic study de-
scribed below), 500 g/ml for LY (paracellular integrity marker), and 10
M for digoxin (P-glycoprotein [P-gp] marker substrate). After 1 h of
incubation at 37°C in a tissue culture incubator (transport was linear
within 1 h; data not shown), samples were removed from both apical and
basolateral chambers and analyzed for diamidine, digoxin, and midazo-
lam concentrations by UPLC-MS/MS. LY concentrations were measured
using a fluorescence microplate reader (FL600; Bio-Tek, Winooski, VT)
with excitation and emission wavelengths of 485 and 530 nm, respectively.
Transepithelial electrical resistance (TEER) values were measured for each
insert to confirm the integrity of the monolayers. Only samples with ac-
ceptable TEER values (130  · cm2) were used for analysis. Apparent
permeability (Papp [cm/s]) was calculated as follows: Papp  [Vr/(S  C0)] 
dCr/dt, where Vr is the volume of medium (ml) in the receiver chamber, S
is the surface area (cm2) of the cell monolayer, C0 is the initial concentra-
tion (M) of the compounds in the donor chamber, and dCr/dt is the
linear slope of the compound concentration in the receiver chamber over
time (M/s). Efflux ratios (RE) were calculated as the ratio of Papp,B-A over
Papp,A-B. Net flux ratios were calculated by dividing the efflux ratio in
MDR1-MDCK cells by that in WT MDCK cells; a ratio greater than 2 is
indicative of a P-gp substrate according to FDA guidance (18). Mass bal-
FIG 1 Chemical structures of cationic diamidines.
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ance (%), defined as the percentage of the amount of compound recov-
ered in the apical and basolateral chambers relative to the initial amount
in the donor chamber, was calculated for each transport study as follows:
mass balance (%)  {[(Cd  Vd) 	 (Cr  Vr)]/(C0  Vd)}  100, where
Vd is the volume of medium (ml) in the donor chamber, Vr is the volume
of medium (ml) in the receiver chamber, Cd and Cr are the compound
concentrations (M) in the donor and receiver chambers, respectively,
and C0 is the initial compound concentration (M) in the donor
chamber.
Plasma and tissue binding assays. The binding of cationic diamidines
to mouse plasma and brain was evaluated by the equilibrium dialysis
method using the rapid equilibrium dialysis device (Thermo Scientific
Pierce, Rockford, IL) as described previously (19). Briefly, blank (un-
treated) mouse brains were collected and homogenized in two volumes
(vol/wt) of water (3-fold dilution). Diamidines were spiked into blank
plasma or brain homogenates to give final drug concentrations of 1 and 5
M. Spiked plasma or brain homogenates were added to the dialysis de-
vice and dialyzed against phosphate-buffered saline (PBS) for 6 h at 37°C
to reach equilibrium between the plasma/tissue compartment and the
buffer compartment. At the end of the incubation, samples from the plas-
ma/tissue compartment and the buffer compartment were collected and
analyzed for total (bound plus unbound) and unbound drug concentra-
tions, respectively, by UPLC-MS/MS. Unbound fractions in the mouse
brain (fu,brain) were calculated by correcting for dilution using the follow-
ing equation (20): fu,brain  (1/D)/{[(1/fu,dilute)  1] 	 1/D}, where D is
the dilution factor for the mouse brain homogenates (D  3) and fu,dilute
is the unbound fraction measured in the mouse brain homogenates.
Pharmacokinetics and brain exposure. The single-dose pharmacoki-
netics of each cationic diamidine were evaluated in mice (in triplicate)
after intravenous (i.v.), oral (per os [p.o.]), and i.p. administration. The
compounds were first dissolved in sterile water and then further diluted to
the desired concentrations with saline (1:1, vol/vol) to avoid precipitation
when added directly to saline. The doses were 7.5 mol/kg for i.v. admin-
istration, 100 mol/kg for p.o. administration, and 65 mol/kg for i.p.
administration. The dose volume was 5 ml/kg. No overt adverse effects
were observed in mice at these dose levels. These doses were either the
same or similar to those used in previous efficacy studies in mice (6, 8).
Blood sampling was done at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h
postdose. Additional earlier sampling times of 0.0167 and 0.083 h for i.v.
administration of DB829 and pentamidine and 0.083 h for i.v. adminis-
tration of DB75 and DB820 were included. Blood (
40 l per bleed) was
collected via the submandibular vein or heart into lithium heparin-coated
Microvet tubes (Sarstedt, Inc., Newton, NC). Terminal blood and brain
samples were collected at 4, 12, and 72 h after i.p. dose. Plasma was ob-
tained by centrifugation. Excised mouse brain samples were quickly
rinsed with distilled water, blotted dry with tissue paper, and weighed. All
samples were stored at 20°C until further processing for quantification
by UPLC-MS/MS.
Sample preparation and UPLC-MS/MS analysis. Thawed mouse
brain samples were mixed with two volumes (vol/wt) of water and ho-
mogenized using a sonic dismembrator (Fisher Scientific, Fair Lawn, NJ).
Plasma (2 l) or brain homogenate (10 l) samples were mixed with 200
l of 7:1 (vol/vol) methanol/water containing 0.1% (vol/vol) trifluoro-
acetic acid and DB75-d8 (5 nM; internal standard), followed by centrifu-
gation to pellet precipitated proteins. The supernatants were dried under
N2 at 50°C using a 96-well microplate evaporator (Apricot Designs, Inc.,
Covina, CA) and reconstituted with 100 l 15% (vol/vol) methanol con-
taining 0.1% (vol/vol) trifluoroacetic acid prior to UPLC-MS/MS analy-
sis. Samples from equilibrium dialysis, metabolic stability, and transport
studies were treated like the plasma and brain homogenate samples and
processed as described above.
The quantification of diamidines, digoxin, and midazolam was per-
formed on a Waters Xevo TQ-S triple-quadrupole mass spectrometer
(Foster City, CA) coupled with a Waters Acquity UPLC I-class system.
The analytical conditions for DB75 and DB820 were the same as those for
pentamidine and DB829 and were described previously in detail (8). The
characteristic single-reaction monitoring (SRM) transitions for pentam-
idine, DB75, DB820, DB829, and DB75-d8 were m/z 341.4¡120.1,
305.2¡288.1, 306.2¡272.1, 307.1¡273.1, and 313.2¡296.3, respec-
tively, under positive electrospray ionization mode. The calibration
curves for the diamidines ranged from 0.005 to 50 M for plasma samples
and from 0.005 to 25 M for brain homogenate samples. The interday
coefficient of variation (CV) and accuracy were determined by measuring
the same preparation of three standards three times on three different
days; deviations for all diamidines were within 15%. The SRM transi-
tions for digoxin and digitoxin (internal standard) were m/z 779.7¡649.5
and 763.6¡633.5, respectively, under negative electrospray ionization
mode. The calibration curve for digoxin ranged from 0.005 to 10 M for
transport samples, and the interday CV and accuracy deviations were also
within 15%. The SRM transition for midazolam was m/z 325.1¡291.1
under positive electrospray ionization mode, and pentamidine was used
as the internal standard. The calibration curve for midazolam ranged
from 0.005 to 10 M for transport samples, and the interday CV and
accuracy deviations were also within 15%.
Pharmacokinetic and statistical analyses. The area under the plasma
concentration-time curve from time zero to time infinity (AUC0-), ter-
minal elimination half-life (t1/2), maximum plasma drug concentration
(Cmax), time to reach Cmax (Tmax), whole body clearance (CL), steady-
state volume of distribution (Vss), and mean residence time (MRT) were
calculated using the trapezoidal rule-extrapolation method (21) and non-
compartmental methods (WinNonlin version 5.3, Pharsight, Mountain
View, CA). One-way analysis of variance (ANOVA) with Tukey’s post hoc
test was used to compare the means of permeability or unbound fraction
of the four diamidines (GraphPad Prism 5.04; GraphPad Software, Inc.,
La Jolla, CA). Student’s t tests (unpaired, two-tailed) were used to com-
pare the mean values for permeability or unbound fraction at two differ-
ent drug concentrations. Statistical outcomes were considered significant
when the P value was 0.05.
RESULTS
Physicochemical properties and metabolic stability of cationic
diamidines. The pKa, logP (logarithm of partition coefficient),
and logD7.4 values for pentamidine, DB75, DB820, and DB829
(Table 1) were experimentally determined using a UV spectro-
photometric method (11). Although a slight decrease in pKa was
observed for azadiamidines compared to the values for pentami-
dine and DB75 (approximately 1 pKa unit), they were still well
above physiologic pH. Hence, like pentamidine and DB75, the
azadiamidines DB820 and DB829 remain positively charged un-
der physiologic conditions. Additionally, all four diamidines were
metabolically stable in mouse liver microsomes supplemented
with NADPH (Table 1). At the longest incubation time (60 min),
the percentage of substrate remaining relative to time zero was
always greater than 87% for each diamidine (data not shown).
Diamidine permeability across MDR1-MDCK cell monolay-
ers. The BBB permeability of cationic diamidines was assessed
using the in vitro MDR1-MDCK cell model (Table 1). Two sub-
strate concentrations, 1 and 10 M, were tested for each di-
amidine. Papp,A-B across MDR1-MDCK cell monolayers ranged
from 1.6  106 to 4.1  106 cm/s for the four diamidines. There
was no significant difference between the two substrate concen-
trations tested (P  0.05), except for DB829 (P  0.012). In addi-
tion, there was no statistically significant difference among the
four diamidines when Papp,A-B was assessed at the 10 M substrate
concentration. The only significant difference observed occurred
between DB75 and pentamidine at 1 M (4.1  106 versus 1.6 
106 cm/s, respectively). The paracellular marker LY exhibited a
low permeability (Papp,A-B  1.0  10
6 cm/s), indicating mono-
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layer integrity. The transcellular marker midazolam showed a
high permeability (Papp,A-B  40  10
6 cm/s) across the MDR1-
MDCK cell monolayers, consistent with its high BBB permeability
in vivo (15). The overall mass balance ranged from 90% to 108%.
Interaction of diamidines with P-glycoprotein. To assess
whether diamidines are substrates of the efflux transporter P-gp,
the net flux ratio of each diamidine was determined using WT
MDCK and MDR1-MDCK cell monolayers (Table 1). All net flux
ratios were less than 2, indicating that none of the four diamidines
was a human P-gp substrate. In comparison, digoxin (P-gp
marker substrate) showed a net flux ratio of 3.7, similar to the
FDA’s reference number of 4 (18), demonstrating that P-gp was
functionally expressed in the MDR1-MDCK cell monolayers used
in our study. The paracellular marker LY exhibited low permea-
bility (Papp,A-B  1.0  10
6 cm/s), indicating monolayer integrity
in all experiments. The overall mass balance ranged between 84%
and 105%.
Diamidine binding in plasma and brain. The nonspecific
binding of each diamidine to mouse plasma proteins and brain
tissues was evaluated at two concentrations, 1 and 5 M (Table 2).
There was no concentration-dependent difference in unbound
fractions for any diamidine in mouse plasma or brain, except for
the brain unbound fraction (fu,brain) of DB820 (0.22% versus
0.40% at 1 and 5 M, respectively; P  0.016). The plasma un-
bound fractions (fu,plasma) varied significantly between the diami-
dines (up to 5.9-fold), ranging from 6.8% for DB75 to 40% for
DB829 (Table 2). Furthermore, the unbound fractions in brain
were considerably lower than those in plasma and varied signifi-
cantly between diamidines (up to 16-fold), ranging from 0.09%
for DB75 to 1.48% for DB829 (Table 2).
Diamidine pharmacokinetics after intravenous and oral ad-
ministration. The plasma concentration-time profiles of pentam-
idine, DB75, DB820, and DB829 were determined after a single i.v.
dose of 7.5 mol/kg or a single p.o. dose of 100 mol/kg (Fig. 2).
All profiles exhibited at least a biphasic decline with an initial
distribution phase and a terminal elimination phase. The pharma-
cokinetic outcomes were determined using noncompartmental
analysis (Table 3). Following i.v. administration, DB829 gave the
highest AUC and the lowest steady-state volume of distribution
(Vss), while pentamidine showed the lowest AUC. The terminal
elimination half-life (t1/2) ranged from 7.2 h for pentamidine up
to 58 h for DB75. Following p.o. administration, little DB75 and
DB820 were detected in the plasma (Cmax  0.016 M). However,
appreciable concentrations of DB829 were detected (Cmax  0.083
M), albeit representing merely 1% oral bioavailability (Table 3).
Diamidine pharmacokinetics and brain exposure after intra-
peritoneal administration. The plasma concentration-time pro-
files of pentamidine, DB75, DB820, and DB829 were determined
after a single 65 mol/kg i.p. dose of each compound (approxi-
mately 20 to 22 mg/kg, depending on the compound’s molecular
weight) (Fig. 3). All profiles exhibited at least a biphasic decline
with an initial distribution phase and a terminal elimination
phase. The pharmacokinetic outcomes were determined using
noncompartmental analysis (Table 4). DB829 showed the high-
TABLE 1 Physicochemical properties, metabolic stability, permeability, and net P-gp flux ratios of cationic diamidinesa



























Pentamidine 11.60  0.01 1.7  0.1 2.0 1 180 1.6  1.1d 99 1.2 0.54  0.40 92 2.2 0.55
10 180 1.6  0.60 98 3.1 0.99  0.47 94 4.9 0.63
DB75 11.80  0.01 2.7  0.1 2.0 1 180 4.1  1.1d 105 0.5 4.8  0.96c 102 0.6 0.83
10.40  0.03 10 180 2.5  0.97 96 0.9 1.4  0.52c 92 2.4 0.38
DB820 11.03  0.29 1.65  0.13 4.90 1 180 2.5  0.42 98 0.8 5.4  1.7 102 0.6 1.3
10.32  0.15 10 180 2.8  1.4 96 0.7 3.1  1.3 98 0.9 0.78
DB829 10.35  0.18 1.21  0.20 4.33 1 180 2.8  0.30c 102 0.8 1.9  0.68 103 0.95 0.84
9.98  0.16 10 180 1.8  0.31c 102 0.8 2.5  0.99 105 1.3 0.62
Digoxin 10 ND 0.34  0.08 90 25 0.78  0.2 91 6.8 3.7
Midazolam 10 ND 40  6.6 108 0.99 50  2.7 103 1.02 0.97
a Values are means  standard deviations unless otherwise indicated. The Papp,A-B values are from triplicate determinations at each concentration.
b Microsomal half-lives of diamidines were determined using NADPH-supplemented mouse liver microsomes. ND, not determined.
c The difference between the results at 1 and 10 M was statistically significant (P  0.05).
d The difference between the results for pentamidine and DB75 was statistically significant (P  0.05).





% fu (mean  SD)
a in:
Plasma Brain
Pentamidine 1 8.4  1.2b 0.3  0.1
5 10  1.2 0.5  0.1
DB75 1 6.8  0.7 0.1  0.05
5 8.0  0.4 0.09  0.01
DB820 1 21  2.0 0.2  0.05c
5 19  2.4 0.4  0.06c
DB829 1 40  8.2b 1.5  0.3
5 36  3.3 1.4  0.4
a fu, drug unbound fraction. Results are from triplicate determinations.
b Previously published value (8).
c The difference between the results at 1 and 5 M was statistically significant
(P  0.05).
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est systemic exposure (AUC0-  73.9 M · h and Cmax  31.6
M) among the diamidines, whereas pentamidine and DB75
were the lowest. The terminal elimination half-life (t1/2) also
exhibited variability, ranging from approximately 21 h for
DB829 to 42 h for DB820.
The total brain concentration of each diamidine was measured
at 4, 12, and 72 h postdose. Similar to plasma, DB829 showed the
highest total brain concentrations, ranging from 5.7 to 8.7 M,
whereas pentamidine had the lowest, ranging from 0.51 to 0.7 M
(Fig. 3A and D). DB75 and DB820 had intermediate total brain
concentrations of 1.2 to 2.8 M and 2.1 to 4.6 M, respectively
(Fig. 3B and C). Compared to the corresponding plasma concen-
trations, all diamidines showed high brain-to-plasma (B/P) ratios.
At 72 h postdose, DB829 had the highest B/P ratio, 114, followed
by DB75, DB820, and pentamidine (Table 4). The B/P ratios in-
creased as the time postdose increased from 4 h to 72 h, suggesting
that it took longer than 12 h to reach equilibrium between brain
and plasma, and hence, the B/P ratios at 72 h may be more repre-
sentative of steady-state B/P ratios. Furthermore, DB829 had the
greatest AUC in the brain, followed by DB820, DB75, and pent-
FIG 2 Plasma concentration-time profiles of cationic diamidines following intravenous (filled circles) or oral (open circles) administration to healthy mice. A
single dose of pentamidine, DB75, DB820, or DB829 was administered i.v. (7.5 mol/kg, or approximately 2.3 to 2.6 mg/kg) or p.o. (100 mol/kg, or
approximately 30 mg/kg) to male Swiss Webster mice. Symbols and error bars represent means and standard errors of triplicate determinations.
TABLE 3 Pharmacokinetic parameters of cationic diamidines after i.v. and p.o. administration to mice
Route
Parametera (unit of
measure) Pentamidineb DB75 DB820 DB829b
i.v. Dose, [mol/kg (mg/kg)] 7.5 (2.6) 7.5 (2.3) 7.5 (2.3) 7.5 (2.3)
C5 min (mol/liter) 0.74  0.21 9.6  0.25 5.2  2.5 9.0  4.6
AUC0- (mol/liter · h) 1.2 5.2 4.9 7.6
t1/2 (h) 7.2 58 24 18
CL (liters/h/kg) 6.3 1.5 1.5 0.98
Vss (liters/kg) 23 41 23 7.1
MRT (h) 3.6 28 15 7.2
p.o. Dose [mol/kg (mg/kg)] ND 100 (30) 100 (30) 100 (30)
Cmax (mol/liter) ND 0.008 0.016 0.083
Tmax (h) ND 0.5 1 1
AUC0- (mol/liter · h) ND 0.13
c 0.31 1.01
t1/2 (h) ND 107 26 21
F (%) ND 0.2 0.5 1.0
a Abbreviations: C5 min, plasma concentration at 5 min postdose; Cmax, maximum plasma concentration; t½, terminal elimination half-life; Tmax, time to reach Cmax; AUC0-, area
under the plasma concentration-time curve from time zero to infinite time; CL, clearance; Vss, steady-state volume of distribution; F, oral bioavailability; MRT, mean residence
time; ND, not determined.
b The i.v. PK measurements for plasma were previously published (8).
c AUC was calculated for 0 to 72 h, as extrapolation beyond 72 h would account for 30% of total AUC.
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amidine (Table 4). In contrast, when plasma-to-brain unbound
fraction ratios (fu,plasma/fu,brain) were compared, DB829 and pent-
amidine had the lowest ratios, whereas DB75 had the highest
(Table 4).
Drug exposure-effect relationships. To explore the relation-
ships between pharmacodynamics and different pharmacokinetic
outcomes of cationic diamidines, drug effect (i.e., in vivo efficacy)
was plotted against various definitions of drug exposure (Fig. 4
and 5). Relevant in vitro antitrypanosomal activities and in vivo
efficacies of cationic diamidines (see Table S1 in the supplemental
material) were previously published by Wenzler et al. (6). For
first-stage HAT using the T. b. rhodesiense STIB900 acute mouse
model, drug efficacy was compared to plasma Cmax and AUC,
unbound plasma Cmax and AUC, and IC50-normalized unbound
plasma Cmax and AUC (Fig. 4). AUC-based measurements exhib-
ited a straightforward relationship with drug effect (Fig. 4B, D,
and F), which resembled the upper portion of a dose-response
curve defined by the Emax model (22).
For second-stage HAT using the T. b. brucei GVR35 CNS
mouse model, drug efficacy was compared to drug brain concen-
tration and AUC, unbound brain concentration and AUC, and
IC50-normalized unbound brain concentration and AUC, as well
as B/P ratio and unbound plasma-to-brain fraction ratio (Fig. 5).
Because different dose regimens were used in the previous efficacy
testing (see Table S1 in the supplemental material), DB75 drug
exposures were dose corrected, assuming a linear dose-exposure
relationship in the small dose range of 12.5 to 20 mg/kg. Although
pentamidine was not directly tested at 10 doses of 20 mg/kg/day
i.p. in the GVR35 CNS mouse model, it is reasonable to expect that
it would not be curative at this dose, since 10 doses of 12.5 mg/kg/
day was not curative (see Table S1). The results showed that there
was, in general, a linear relationship between CNS efficacy and
drug exposure. The B/P ratio showed the best correlation (R2 
0.94) with the CNS efficacy of all four cationic diamidines (Fig.
5G). The unbound brain concentration (Fig. 5C) and AUC (Fig.
5D) also gave good correlations (R2  0.94); however, no defini-
tive conclusion could be drawn due to the lack of data points for
intermediate efficacy.
DISCUSSION
It is extraordinary that the cationic azadiamidine DB829 was able
to completely cure mice and monkeys with second-stage HAT
infections in spite of the long-held notion that cationic diamidines
(positively charged at physiologic pH) lack the necessary passive
FIG 3 Plasma (filled circles) and brain (open squares) concentration-time profiles of cationic diamidines following intraperitoneal administration to healthy
mice. A single dose of pentamidine, DB75, DB820, or DB829 was administered i.p. (65 mol/kg, or approximately 20 to 22 mg/kg) to male Swiss Webster mice.
Symbols and error bars represent means and standard errors of triplicate determinations.
TABLE 4 Pharmacokinetic parameters of cationic diamidines after i.p.
administration to mice
Parametera (unit of measure) Pentamidineb DB75 DB820 DB829b
Dose [mol/kg (mg/kg)] 65 (22) 65 (20) 65 (20) 65 (20)
Cmax (mol/liter) 6.66 5.33 30.5 31.6
t1/2 (h) 34.4 21.9 41.7 21.2
Tmax (h) 0.25 0.25 0.25 0.50
AUC0- (mol/liter · h) 10.7 15.9 37.2 73.9
Cbrain_72h (mol/liter) 0.579 2.84 4.55 8.35
AUCbrain_0–72h (mol/liter · h) 39 169 275 508
B/P ratio at 72 h 22.8 65.5 44.5 114
fu,plasma/fu,brain
c 23 74 67 25
a Abbreviations: Cmax, maximum plasma concentration; t1/2, terminal elimination half-
life; Tmax, time to reach Cmax; AUC0-, area under the plasma concentration-time curve
from time zero to infinite time; Cbrain_72h, brain concentration at 72 h postdose;
AUCbrain_0-72h, area under the brain concentration curve from time zero to 72 h
postdose; B/P, brain-to-plasma concentration ratio; fu, drug unbound fraction.
b The plasma PK measurements were previously published (8).
c The unbound fractions were averaged using values determined with final drug
concentrations of 1 and 5 M (Table 2).
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permeability to traverse the BBB to kill trypanosomes residing in
the CNS. Hence, a better understanding of the biochemical mech-
anisms underlying the differential efficacies of cationic diamidines
is warranted to further assist in the development of diamidine-
based chemotherapies against second-stage HAT. In this study, a
pharmacokinetic characterization was conducted to compare the
plasma and brain exposures of four representative cationic diami-
dines, pentamidine, DB75, DB820, and DB829, and to explore the
relationship between drug exposure and effect.
All four diamidines showed a long microsomal half-life (Table
1), indicating that little metabolism occurred during incubation
with mouse liver microsomes. Pentamidine was the least stable
when the percentage of substrate remaining at the end of incuba-
tion (t  60 min) was compared. Pentamidine was shown previ-
ously to be metabolized by rat liver microsomes and isolated per-
fused rat livers via hydrocarbon chain hydroxylation (major
pathway) and amidine N-hydroxylation (minor pathway) (23).
Hence, the replacement of the pentyl linker between two aromatic
amidine groups with a furan linker (Fig. 1) appears to have re-
duced the susceptibility to metabolism in mice, which could have
contributed to the greater plasma AUC values observed for diami-
dines with a furan linker (Tables 3 and 4). In addition, these met-
abolically stable furan linkers are not expected to be mutagenic, as
they did not pose this problem for pafuramidine (24) or antileish-
manial arylimidamides (12).
In general, cationic diamidines had low levels of permeability
(0.54  106 to 5.4  106 cm/s) across MDCK cell monolayers
(Table 1), consistent with the notion that they lack the necessary
passive permeability to efficiently cross either the enteric barrier
or the BBB (25, 26). This was further supported by the extremely
low oral bioavailability of cationic diamidines (F  1%) (Table 3).
Nonetheless, there appeared to be an upward trend in oral absorp-
tion for the azadiamidines DB820 and DB829. For example,
DB829 had 5-fold higher oral bioavailability than DB75 (1% ver-
sus 0.2%) and reached a maximal plasma concentration of 0.083
M after a single oral dose of 100 mol/kg (30 mg/kg) (Table 3).
FIG 4 Drug exposure-effect relationships of cationic diamidines in the T. b. rhodesiense STIB900 acute mouse model. Dotted lines connect data points from
pentamidine, DB75, DB820, and DB829, respectively. Relevant in vitro antitrypanosomal activities and in vivo efficacies of cationic diamidines were previously
published by Wenzler et al. (6) and are summarized in Table S1 in the supplemental material.
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This explains our previous observation that DB829, administered
orally at 4 doses of 50 mg/kg/day, cured 3/4 mice with acute T. b.
rhodesiense STIB900 infections (antitrypanosomal IC50 of 0.0147
M for DB829) (8).
None of the diamidines examined appeared to be a substrate of
the human MDR1 efflux transporter (Table 1), indicating that
P-gp-mediated efflux was unlikely to be the cause of the differen-
tial CNS activity observed with the cationic diamidines. It is un-
known whether these diamidines are substrates of the other hu-
man P-glycoprotein, MDR3, although there is little evidence that
MDR3 plays a major role in the transport of drugs (27). However,
pentamidine was shown previously to be a substrate of mouse
P-gp (Mdr1a/b) via in situ brain perfusion of FVB Mdr1a/
Mdr1b/ knockout mice (5). These results suggest that the in-
teraction of cationic diamidines with the P-gp efflux transporter is
species dependent.
Each cationic diamidine differed markedly in its nonspecific
binding to plasma proteins and brain tissues. Among the four
FIG 5 Drug exposure-effect relationships of cationic diamidines in the T. b. brucei GVR35 CNS mouse model. Dotted lines connect data points from
pentamidine, DB75, DB820, and DB829, respectively. Solid lines represent least-square linear regressions. Relevant in vitro antitrypanosomal activities and in vivo
efficacies of cationic diamidines were previously published by Wenzler et al. (6) and are summarized in Table S1 in the supplemental material.
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diamidines, DB75 bound most avidly to both plasma proteins and
brain, whereas the azadiamidine DB829 showed the least binding
(Table 2). The binding to brain greatly exceeded that to plasma
proteins, by 23- to 74-fold (Fig. 5H), resulting in the apparent
volumes of distribution being greater than the physiologic fluid
volumes for the cationic diamidines (Table 3). Yan et al. (19)
previously demonstrated that hepatic binding underlay the differ-
ences in systemic exposure of DB75 and DB829, which are both
formed from their methamidoxime prodrugs (pafuramidine and
DB868, respectively) in the rat liver. Hence, it can be postulated
that binding to brain, as well as other tissues where diamidines
distribute, could also underlie the differences in systemic exposure
of the cationic diamidines when administered parenterally. This
warrants further compartmental pharmacokinetic investigation
once the binding of diamidines in other tissues is determined.
The activity of the cationic diamidines against acute T. b. rho-
desiense STIB900 infections appeared to be more AUC dependent
than Cmax driven (Fig. 4). This is consistent with our previous
observation (8) that the in vitro antitrypanosomal activity of
DB829 did not increase with drug concentrations greater than 2
M, likely due to the saturation of the P2 transporter-mediated
uptake into trypanosomes. This property may prove to be desir-
able, because dosing regimens can be adjusted (e.g., longer or
more frequent) to use lower doses for better safety, assuming tox-
icity is Cmax driven. Although it appeared to have followed the
dose-response curve defined by the Emax model (Fig. 4B, D, and F)
(22), the drug exposure-effect relationship needs to be further
defined using a pharmacokinetic-pharmacodynamic modeling
approach with drug exposure and efficacy determined at multiple
dose levels.
The activity of the cationic diamidines against CNS T. b. brucei
GVR35 infections showed a good linear correlation with the B/P
ratio at 72 h postdose (Fig. 5G). The B/P ratio, also known as the
brain/plasma partition coefficient (Kp,brain), is the most widely
used in vivo parameter to evaluate the extent of CNS penetration.
A Kp,brain of 1 often indicates “good” CNS penetration, while a
Kp,brain of 1 suggests “poor” CNS penetration (28); however,
exceptions to this arbitrary Kp,brain cutoff exist, such as the anti-
psychotic drug sulpiride (0.078) and the sedative midazolam
(0.23) (29). Surprisingly, all cationic diamidines examined in this
study showed high B/P ratios, ranging from 23 for pentamidine up
to 114 for DB829 (Table 4), suggesting good CNS penetration.
However, only DB829 cured mice with CNS T. b. brucei GVR35
infections (6). Using fluorescence microscopy, Sturk et al. (30)
previously demonstrated that DB75 did not distribute into brain
parenchyma. Instead, it was sequestered within endothelial cells
lining the BBB and blood-cerebrospinal fluid (CSF) barrier.
Hence, the B/P ratio alone is not a good predictor for CNS activity
of cationic diamidines against second-stage HAT. Our results,
however, showed that the B/P ratio could be used to rank cationic
diamidines in terms of CNS activity within the same compound
class.
The in vitro plasma-to-brain unbound fraction ratios (fu,plasma/
fu,brain) did not correlate with the CNS activities of the cationic
diamidines (Fig. 5H). Several papers have reported the use of the
fu,plasma/fu,brain ratio to predict the B/P ratio of CNS and non-CNS
compounds (20, 29, 31, 32). Good agreement has been observed
for compounds that do not exhibit active efflux at the BBB,
whereas the fu,plasma/fu,brain ratio overpredicted the B/P ratio for
compounds that are actively effluxed (e.g., P-gp substrates). To
account for P-gp-mediated efflux at the BBB, the fu,plasma/fu,brain
ratio was corrected using the efflux ratio and subsequently showed
an improved correlation with the in vivo B/P ratio (32). However,
since cationic diamidines are not subjected to P-gp-mediated ef-
flux (Table 1), it is not expected that the efflux ratio correction
would improve prediction of the in vivo B/P ratio by the in vitro
fu,plasma/fu,brain ratio.
The fu,plasma/fu,brain ratio appears to have underpredicted the
B/P ratio of the CNS-active DB829 (Table 4). This may be ex-
plained by preferential uptake of the azadiamidine DB829 via an
uptake transporter(s) expressed at the apical (blood luminal) side
of the BBB. Pentamidine and DB75 are good substrates for human
organic cation transporter 1 (hOCT1) and weak substrates for
hOCT2 but not for hOCT3 (33). hOCT1 is highly expressed in
hepatocytes but not in the brain, whereas hOCT2 can be found in
renal proximal tubules and neurons (34). The hOCT1-mediated
hepatic sequestration of DB75 after intestinal absorption may
contribute to its lower oral bioavailability compared to those of
DB820 and DB829 (Table 3). However, it is unknown whether
DB820 and DB829 also are substrates for these transporters, and
the roles these transporters may have in mediating the uptake of
diamidines into the CNS are largely unexplored. In addition, sev-
eral trypanosomal transporters have been implicated in the uptake
of cationic diamidines into trypanosomes. These include the P2
aminopurine transporter (TbAT1) (35–37) and aquaglyceroporin
2 (38). The P2 aminopurine transporter belongs to the nucleoside
transporter family. In mammals, the nucleoside transporter fam-
ily consists of three concentrative nucleoside transporters (CNTs)
and four equilibrative nucleoside transporters (ENTs), which are
expressed in the brain and various other tissues (39). It can be
postulated that azadiamidines are substrates of mammalian nu-
cleoside transporters and preferentially transported into the brain,
which warrants future investigation.
In conclusion, pharmacokinetics (i.e., AUC, tissue binding,
and CNS penetration) play an important role in determining the
in vivo efficacies of cationic diamidines against first- and second-
stage HAT. The azadiamidine DB829 showed higher systemic ex-
posure, less tissue binding, and greater CNS penetration, which
contributed to its excellent in vivo efficacy in animal models of
both first- and second-stage HAT. Our results further support
DB829 as a preclinical candidate for the treatment of second-stage
HAT. In addition, better understanding of the uptake transport
mechanisms of azadiamidines at the BBB will be important for
defining the pharmacokinetic-pharmacodynamic relationship for
antitrypanosomal diamidines, as well as for the brain uptake of
CNS drugs in general.
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